{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-014278","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2024-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.874520+00:00","generated_at":"2026-06-04T00:01:27.120711+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"medium","headline":"Processa presents NGC-Cap Phase 1b data at AACR; poster modified","bullets":["David Young, President R&D, presented two abstracts at AACR 2024 on NGC-Cap and Project Optimus.","NGC-Cap Phase 1b data shows significantly increased 5-FU exposure and improved safety vs capecitabine.","The originally presented poster was subsequently modified; amended posters posted on company website.","Second abstract addresses optimal dose using Phase 1 and preclinical data under Project Optimus.","No specific numerical results disclosed in filing; detailed data available in website publications."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-014278","json":"https://secwatch.observer/filing/0001493152-24-014278.json","markdown":"https://secwatch.observer/filing/0001493152-24-014278.md","text":"https://secwatch.observer/filing/0001493152-24-014278.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224014278/0001493152-24-014278-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224014278/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T00:01:27.120711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}